Effect of Dispersion Medium on Pharmacokinetic Profile of Rotigotine Crystalline Suspension following Subcutaneous Injection

Rotigotine (RTG) is prescribed as a once-daily transdermal patch for managing early Parkinson’s disease (PD), which presents issues such as skin irritation and poor patient adherence. Therefore, the aims of the present study were to formulate aqueous and oily vehicle-based RTG crystalline suspension...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Min Seop, Ho, Myoung Jin, Joung, Min Yeong, Choi, Yong Seok, Kang, Myung Joo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9784203/
https://www.ncbi.nlm.nih.gov/pubmed/36559123
http://dx.doi.org/10.3390/pharmaceutics14122630

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9784203/
https://www.ncbi.nlm.nih.gov/pubmed/36559123
http://dx.doi.org/10.3390/pharmaceutics14122630

Ejemplares similares